Cannabis activists across Ireland, the UK and Spain are aiming to walk over 2,000km to highlight the distance that cannabis patient and activist Alicia Maher has to travel to access her medication.
The Irish campaign started on Sunday 26 September to coincide with the second annual National Walking Day but it has since been extended for the week. Activists were encouraged to get out and walk, run or cycle a minimum of 2km while tweeting their participation in the campaign.
Several Irish ministers were tagged in tweets calling for changes to cannabis access including Frank Feighan, Public Health, Well Being and National Drugs Strategy and Stephen Donnelly, Minister for Health.
Speaking to Cannabis Health News, Alicia said: “Martin Conway from Martin’s World actually organised the campaign. He noticed that Frank Feighan had been made an ambassador for National Walking Day so he came up with the idea for the campaign.
“We wanted to get as many people to walk as possible to cover the distance it would take to walk from Cork to Alicante which is 2,055 km.”
She added: “It’s really taken off. I can’t believe how many people are taking part. We think we have gone over the 2055 kilometres and now we are doing the way back.”
Just back from a 10.6km run for #BringAliciaHome @FrankFeighan @DonnellyStephen how far do you want us to go in this campaign for the patients who need cannabis for a better quality of life? #CannabisReformIreland#NWD2021 @pfsa_ireland pic.twitter.com/MDnspMvaMO
— Martin’s World (@MartinsWorld420) September 28, 2021
Alicia said there have been people walking in countries including Ireland, UK, Spain, Portugal, America, Canada, Australia, and Thailand. She is hopeful that the ministers tagged in the tweets can see the demand for access.
“I hope that Stephen Donnelly might see it,” she said.
“I’m already tagging him in hundreds of posts and I’ve emailed him but received an answer copy and pasted from the internet. I wrote back repeating my questions which was two months ago, I’ve heard nothing since.”
Irish cannabis activism
Alicia left Ireland last year to access medical cannabis to treat her chronic pain. Ireland’s Medical Cannabis Access Programme (MCAP) does not include chronic pain, leaving Alicia struggling to find £2,000 every three months for her medication.
It’s now been one year since we moved from Ireland to Spain to access #cannabis to treat my #ChronicPain. @DonnellyStephen, you have not acknowledged a single email from me, can you please sort out the Medical Cannabis Access Programme as I would like to be able to return home. https://t.co/iYygCF8CNH
— Alicia Maher (@AliciaLMaher) November 17, 2020
She would like to return home and have access to cannabis in Ireland covered by the medical card system or long-term illness scheme. However, recent updates announced to the Medical Cannabis Access Program show no signs of including patients living with chronic pain.
The campaign progress can be seen on Twitter under the hashtag, #BringAliciaHome
Medical Cannabis Awareness Week returns with call for real world evidence
Three years since the law changed supporters call for regulators to consider real world evidence
Medical Cannabis Awareness Week will return to mark three years since the law changed, with a fresh call for regulators to consider real world evidence and ensure fair access for patients.
Led by patient advocacy group, PLEA (Patient-Led Engagement for Access), Medical Cannabis Awareness Week takes place in the first week of November and brings together patients, doctors, supporters and stakeholders across the sector to raise awareness of the plea for fair access to medical cannabis.
On 1 November 2018, medical cannabis was made available on prescription in the UK. Three years on, only three prescriptions have been issued by the NHS.
Out of desperation, patients are now funding private prescriptions and up to 1.4 million patients are forced to turn to illegal methods.
Patients unable to afford and access treatment are suffering due to the fear, stigma and financial barriers preventing them accessing this safe, and potentially life-changing, treatment.
The first Medical Cannabis Awareness Week to take place last year saw over 50 speakers and 1500 live attendees, with 60,000 people reached.
This year, taking place from 1-7 November, Medical Cannabis Awareness Week 2021 aims to highlight the real need for real-world evidence in evolving access to this new treatment, calling for fair access to medical cannabis treatment on the NHS.
Patients from across the UK will be sharing their stories about the life-changing impact of medical cannabis and their difficulties in accessing a prescription.
Gillian Flood, member of PLEA’s Management Committee who is prescribed medical cannabis for fibromyalgia and PTSD, commented:“Life before and after cannabis medicine really is like night and day, before constant pain left me feeling hopeless and depressed, unable to function, trying all different medications, dealing with awful side effects. After, well, I feel like me again, I can enjoy a meal, go for a walk, sleep and manage my pain better while having a clear head.
“While all this is amazing the financial cost bring a whole new anxiety around how I afford my medicine, every month I struggle to pay for it, I don’t want to go back to my life before, not now I know I don’t have to suffer so much, there is a relief available, my plea is that this medication becomes available through the NHS so no patient has to endure the pressure of trying to fund a private prescription.”
How you can get involved
There are several ways supporters can get involved, with virtual events taking place each day, aimed at patients, doctors, supporters and anyone else with an interest in medical cannabis.
Join patients, advocates and organisations to help raise awareness, address the stigma and call for change by sharing a video or audio clip or written post of your PLEA on social media using the hashtag #MCAW2021.
Have a conversation about medical cannabis. Ask questions, and connect with medical cannabis supporters, patients, and allies via the #MCAW2021 hashtag on social media.
Help spread the word about fair access to medical cannabis treatment by writing to your MP.
Abby Hughes, chair of PLEA commented: “Having witnessed the transformation of quality of life for many patients like myself, it is hard to accept that the only access many have to medical cannabis treatment is through the private sector. Why is there enough evidence for a private pain consultant or psychiatrist to prescribe unlicensed cannabis medicines, yet the same treatment is not afforded to patients via the NHS, which was created to provide universal, comprehensive and free health care?
“With only three NHS prescriptions having been issued three years on from Sajid Javid’s promise to make medical cannabis treatment accessible, my plea for Medical Cannabis Awareness Week 2021 is that the real need for real world evidence is explored and accepted in evolving access to this new treatment.”
We’ll be sharing more details of all the events and how you can get involved in the coming days.
For full event listings and to access resources for patients, doctors and supporters visit www.pleacommunity.org.uk/mcaw
Cannabis and driving – Calls for urgent law reforms to protect patients
A new report highlights the myriad of issues facing medical cannabis users on the road.
Campaigners are calling for urgent reforms to legislation around cannabis and driving as patients risk criminalisation.
A new report, published by the Seed Our Future campaign, highlights the myriad of issues facing medical cannabis users on the road.
The group, which lobbies for the decriminalisation of cannabis, is calling for the removal of THC from Section 5 and reverted to Section 4 of the Road Traffic Act 1988 (RTA), where evidence of impairment would be required to convict.
Following an amendment to the RTA in March 2015, any driver who is stopped by the police can expect to be swabbed and if THC is identified, a blood test is enough to secure a conviction.
This means that anyone who has consumed cannabis within the last few days – or has been subject to passive smoking – may be over the zero-THC limit and at risk of prosecution, regardless of whether there is evidence of impairment.
According to the report, the effects of THC have generally gone after two to four hours when inhaled, longer when orally ingested. And the research conducted by Seed Our Future has found no cases of any serious vehicle accidents which conclusively shows cannabis as the primary cause.
Patients facing criminalisation
Although patients who hold a legal prescription have a right to a medical defence, this is not always taken into account and those who are unable to afford one are being criminalised and having their licences removed without any evidence of driving impairment, argues the report.
In 2021 alone, Seed our Future has supported four people with legal cases in relation to cannabis driving offences. All four suffer from long-term conditions and fit the criteria for obtaining medical cannabis prescriptions, with one holding a legal prescription at the time and two accessing one shortly after arrest.
In all cases, the subjects had taken cannabis several hours before driving and there was no evidence of any sign of driving impairment.
According to the report, in 75 per cent of the cases, the police had “no idea” that the law had changed regarding medical cannabis in 2018.
Seed our Future claims that the inclusion of cannabis in Section 5 of the RTA was based on “political and financial motivations” and not “conclusive road safety data”.
The report concluded: “The concept that a laws exists which leads to a criminal record, fines and a driving disqualification without any evidence of the defendant being a risk to road safety, whom with all likelihood is practicing their inalienable human right to health by utilising globally recognised essential medicine risks jeopardising the fabric and integrity of the judicial system and exposes the incompetence of the police force in being able to gather evidence sufficient to constitute criminal intent.”
Calls for standardisation
Guy Coxall, the groups founder is also asking for standardisation of labelling for medical cannabis prescriptions and health practitioner advice in regard to guidance for driving.
He has called on the Cannabis Industry Council to ensure all importers of cannabis-based products have the correct labelling, in line with UK regulations, and all practitioners provide advice to patients in line with guidance from the Medical Cannabis Clinicians Society (MCCS).
It states: “Patients, on higher THC products especially, should be warned not to drive or operate heavy machinery whilst under the influence of side effects of a cannabis product… Like any other medications that may cause impairment, do not drive or operate a vehicle if feel impaired or are unsure if you feel impaired and follow your physician’s advice.”
Coxall said: “This lack of standardisation places a number of UK patients in danger of criminalisation and penalties.
“We would also like to see discussions surrounding basic educational programmes for Police Officers, CPS solicitors and Judges to update on legislative changes and provide information to reduce stigma and medical and financial discrimination against medical cannabis users/patients, as identifying ways of protecting medical cannabis users who are at present unable to afford private medical prescriptions until availability is made accessible on the NHS.”
GMC must address “serious concerns” over BPNA guidelines on prescribing medical cannabis
An open letter has been signed by more than 30 parents and carers of children with intractable epilepsy
Dozens of parents whose children rely on medical cannabis have written to the General Medical Council (GMC) outlining their concerns about the blocks to access.
More than 40 parents and carers of children who are prescribed medical cannabis to treat conditions such as intractable epilepsy have signed an open letter to the GMC outlining a number of issues.
Earlier this week, 50 medical professionals issued a letter from the Medical Cannabis Clinician’s Society, expressing their concerns over the British Paediatric Neurology Association (BNPA) guidelines on prescribing unlicensed cannabis medicines.
The letter, which was published in the Times, claims that the guidelines play a part in denying medical cannabis treatment for children with epilepsy, many of whom have had their lives significantly improved it.
It includes a comment from an expert witness in a case brought to the GMC by the BPNA, reported as stating that: ‘The BPNA position that only paediatric neurologists should initiate treatment is not supported by other national guidance, and probably not in the best interests of children, as it may impede debate and research into the appropriate use of Cannabidiol (sic) in refractory epilepsy’.
In response the parents of these children say they felt moved to write directly to the GMC to express “serious concerns”.
In the letter they stress that they feel the guidance issued by the BPNA plays a significant role in preventing doctors from prescribing.
It states: “The quote from the GMC expert witness highlights that the BPNA guidance is ‘not supported by other national guidance’.
“From our knowledge of these matters, we believe that this other national guidance may well be that from NHS England, NICE and indeed, to some extent, your own.
“If a professional medical body is producing guidance that is ‘probably not in the best interests’ of the patient cohort at issue, surely that matter should be investigated and then appropriate steps taken to ensure that the guidance in question is corrected?
Speaking with Cannabis Health, Joanne Griffiths, mother of Ben, 11, who suffers from treatment-resistant epilepsy, said: “We felt moved, as a group of parents and carers with loved ones affected by intractable epilepsy, to write to the GMC to ask that they address what we believe to be serious concerns relating to the BPNA position on the prescription of medical cannabis following the recent article in The Times.”
Joanne added: “This is clearly extremely concerning and needs to be addressed. The almost total block on NHS prescriptions is causing untold huge emotional and financial distress to our families.”
The letter states: “Without exception our loved ones have shown very significant improvements in their symptoms following the administration of medical cannabis.
“In many cases, the improvements could more accurately be described as ‘dramatic’ with children who were suffering up to hundreds of seizures a day and being rendered semi-comatose due to the effects of conventional pharmaceutical drugs being able to lead almost normal drugs.
“However, since the law change, to the best of our knowledge, there have only been three NHS prescriptions for whole-plant extract medical cannabis for cases of paediatric epilepsy. The rest of us have had to face the daunting and emotionally and financially draining burden of having to find up to £2,000 a month to fund the medicine privately
“Raising this money is a massive challenge in normal times. During Covid, it has been impossible.”
The parents have now called on the GMC to address their concerns, stating that failure to do so may mean doctors may be “unwittingly failing” in their ethical duty to patients.
Introducing our new B2B title
- BPNA publishes new guidance on prescribing medical cannabis in epilepsy
- 71% of CBD users self-determine dosage without professional help
- Menopause: Could CBD offer relief from symptoms?
- “The system needs to change” – Father desperate to access medical cannabis for his disabled son
- “Millions of cannabis patients face criminalisation behind the wheel – even if completely unimpaired”
- CBD guides: Can CBD help with depression?
News11 months ago
Community extends support to cannabis icon Rick Simpson
News1 year ago
NHS lines up cannabis medicine manufacturing
Case Studies2 years ago
CBD oil and fibromyalgia – a case study
News1 year ago
Cancer survivor claims cannabis oil helped her beat brain tumour
Insight1 year ago
I’ve gone from a wheelchair to walking thanks to cannabis
News10 months ago
UK grants second licence to grow high-THC medical cannabis
Feature1 year ago
Medical cannabis could help long-term effects of COVID-19, says David Nutt
News11 months ago
Living with chronic fatigue – my CBD story